\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

| 1. Name and Address of Reporting Person* SQUINTO STEPHEN P (Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE | | | 2. Issuer Name and Ticker or Trading Symbol <u>ALEXION PHARMACEUTICALS INC</u> [ALXN] | | tionship of Reporting Pers all applicable) Director Officer (give title below) | on(s) to Issuer 10% Owner Other (specify below) |
|--|--|--|---|-------------------------|--|--|
| | | | 3. Date of Earliest Transaction (Month/Day/Year) 11/04/2013 | | EVP, Chief Global Ops. Officer | |
| (Street) CHESHIRE CT 06410 (City) (State) (Zip) | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indivi Line) X | idual or Joint/Group Filing Form filed by One Repo Form filed by More thar Person | orting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| | | | • | | - | | | | | | |
|---|--|---|------------------------------|---|-----------------------------|---------------|--------------------------------|---|---|---|--|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150.4) | |
| Common Stock, par value .0001 per share | 11/04/2013 | | М | | 7,875 ⁽¹⁾ | A | \$22.9 | 112,061 | D | | |
| Common Stock, par value .0001 per share | 11/04/2013 | | М | | 6,250 ⁽¹⁾ | A | \$42.66 | 118,311 | D | | |
| Common Stock, par value .0001 per share | 11/04/2013 | | S | | 12,886 ⁽¹⁾ | D | \$123.82 ⁽²⁾ | 105,425 | D | | |
| Common Stock, par value .0001 per share | 11/04/2013 | | S | | 1,239(1) | D | \$124.39 ⁽³⁾ | 104,186 | D | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| (e.g., puts, cans, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|-------------------------------------|--|--|--------------------|--|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | Deri Sec Acq or D of (I | umber of vative urities uired (A) visposed D) (Instr. and 5) | 6. Date Exerc Expiration Da (Month/Day/\ | ate | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Option to Purchase Common Stock | \$22.9 | 11/04/2013 | | М | | | 7 , 875 ⁽¹⁾ | 04/28/2010 | 01/28/2020 | Common Stock, par value \$.0001 per share | 7,875 | \$22.9 | 0 | D | |
| Option to Purchase Common Stock | \$42.66 | 11/04/2013 | | М | | | 6,250 ⁽¹⁾ | 05/02/2011 | 02/02/2021 | Common Stock, par value \$.0001 per share | 6,250 | \$42.66 | 0 | D | |

Explanation of Responses:

1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$123.26 - \$124.26. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$124.30 - \$125.30. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Remarks:

<u>/s/ Stephen Squinto</u>

<u>11/05/2013</u> Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.